Tamarix Pharma

Therapies for Apoptosis-driven Diseases

Health Tech & Life Sciences
Non Active, May 2023 ceased to operate
Seed Jerusalem, Israel Founded 2020
LinkedIn
Last updated 2026-06-18
Total raised
Last: 2021-01
Stage
Seed
Founded
2020
Headcount
2
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences

About

Tamarix Pharma is an early-stage biotech company focused on developing novel technologies that restore physiological balance in apoptosis-related diseases.

The company's lead assets are VBIT-4 and VBIT-12, small molecules targeting VDAC1 oligomerization. They were deliberately designed to target a key mitochondrial process known as VDAC1 oligomerization. Their unique mechanism of action represents a highly differentiated approach to potentially treating a variety of acute and chronic conditions resulting from apoptotic cell death.

Funding history · 1 round · — total

Q&A

What is the current operational status of Tamarix Pharma?
Tamarix Pharma is currently inactive and ceased to operate in May 2023.
When was Tamarix Pharma founded?
Tamarix Pharma was founded in July 2020.
What is Tamarix Pharma's primary focus?
Tamarix Pharma is an early-stage biotech company focused on developing novel technologies that restore physiological balance in apoptosis-related diseases.
What are Tamarix Pharma's lead assets?
The company's lead assets are VBIT-4 and VBIT-12, which are small molecules targeting VDAC1 oligomerization.
How many employees does Tamarix Pharma have?
Tamarix Pharma has 1-10 employees.
Which investors participated in Tamarix Pharma's funding round in January 2021?
In January 2021, investors including Israel Biotech Fund.
What is Tamarix Pharma's primary sector?
Tamarix Pharma's primary sector is Health Tech & Life Sciences.
Where is Tamarix Pharma headquartered?
Tamarix Pharma is headquartered in Jerusalem, Israel.

Team · 1

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Tags

pharmaceuticalsneurologybiochemical-compoundscell-therapytherapeuticsbiotechnology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)